

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 89322

Title: New Strategies in the Diagnosis and Treatment of Immune-Checkpoint Inhibitor-Mediated Colitis

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 01489938

Position: Editorial Board

Academic degree: AGAF, FACC, MD

Professional title: Full Professor

Reviewer's Country/Territory: Hungary

Author's Country/Territory: Bulgaria

Manuscript submission date: 2023-10-27

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2023-11-21 16:42

Reviewer performed review: 2023-11-21 17:20

Review time: 1 Hour

| | |
|---|--|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Novelty of this manuscript | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty |
| Creativity or innovation of this manuscript | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation |

| | |
|---|--|
| Scientific significance of the conclusion in this manuscript | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous |
| | Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

SPECIFIC COMMENTS TO AUTHORS

This is a very interesting review article about IMC. The authors have thoroughly and clinically summarized the most recent data on the clinical, pathological, histological, and molecular background of IMC and therapeutic recommendations from several perspectives. However, some points need improvement: According to the search strategy used in the study, this is a systematic review: how were the PRISMA 2020 guidelines followed? Please indicate the flow chart as well. Introduction: "The prevalence of IMC may be lower" – "underestimated" is a better term instead of "lower". In Figure 3, B and C images are from the same tissue section; C has a higher magnification. The B image is unnecessary to show because crypts are not represented lengthwise but crosswise. After corrections, I suggest to accept the manuscript for publication.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 89322

Title: New Strategies in the Diagnosis and Treatment of Immune-Checkpoint Inhibitor-Mediated Colitis

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03721258

Position: Peer Reviewer

Academic degree: PhD

Professional title: Doctor, N/A

Reviewer's Country/Territory: China

Author's Country/Territory: Bulgaria

Manuscript submission date: 2023-10-27

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2023-11-25 07:05

Reviewer performed review: 2023-11-26 07:21

Review time: 1 Day

| | |
|---|--|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Novelty of this manuscript | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty |
| Creativity or innovation of this manuscript | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation |

| | |
|---|--|
| Scientific significance of the conclusion in this manuscript | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous |
| | Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

SPECIFIC COMMENTS TO AUTHORS

Immune-Checkpoint Inhibitor-Mediated Colitis (IMC) is an increasingly recognized adverse event in cancer immunotherapy, particularly associated with immune checkpoint inhibitors (ICIs) such as anti-CTLA-4 and anti-PD-1 antibodies. It is not an interesting manuscript. Authors cannot succeed to present their idea in a clear way adding information to the existing literature.